GlassScriptPhysician profile
Amanda Mckinney
NPI 1568813517
$8,611.04
in general payments reported to CMS, 2019-2025
35 companies · $2,903 in 2025
The $2,903 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $503 · 2022: $1,290 · 2023: $1,047 · 2024: $2,867 · 2025: $2,903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,634 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,634.48 |
| Education | $183.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,631.62 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $746.45 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $701.46 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $685.27 | 2022-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $454.60 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $335.29 | 2024-2025 | Vowst, Zenpep |
| Lilly USA, LLC | $296.30 | 2023-2025 | Omvoh, Zepbound |
| Madrigal Pharmaceuticals | $268.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $243.50 | 2021-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $231.33 | 2023-2025 | Voquezna |
| Enterra Medical, INC. | $213.97 | 2024-2025 | |
| Qol Medical, LLC | $194.72 | 2022-2025 | Sucraid, Sucraid |
| Novo Nordisk INC | $159.82 | 2025 | Wegovy |
| Medtronic, INC. | $146.76 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $103.37 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $99.61 | 2021 | |
| Abiomed | $99.06 | 2024 | Impella |
| Pfizer INC. | $93.47 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $86.47 | 2023-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $77.84 | 2024-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $74.13 | 2023-2024 | Linzess |
| Vivus LLC | $67.08 | 2024-2025 | Qsymia, Pancreaze |
| Evoke Pharma, INC. | $60.66 | 2023-2025 | Gimoti |
| Celltrion USA INC. | $55.26 | 2024-2025 | Vegzelma |
| Ultragenyx Pharmaceutical INC. | $48.10 | 2024 | Crysvita |
| Daiichi Sankyo INC. | $44.67 | 2022-2024 | Injectafer |
| Sandoz INC. | $41.64 | 2025 | Hyrimoz |
| Ipsen Biopharmaceuticals, INC | $39.91 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $36.86 | 2025 | |
| Amgen INC. | $36.55 | 2022 | |
| Ferring Pharmaceuticals INC. | $32.53 | 2025 | Clenpiq |
| Alexion Pharmaceuticals, INC. | $28.69 | 2024 | Ultomiris |
| Nestle Healthcare Nutrition INC. | $26.29 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $24.64 | 2024 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Mckinney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.